#RandySweis showing data from EV-SG-zim in 1st line met #urothelialcancer — small sample size but high ORR 81% including 3 pts w CRs. Pushing depth of response for met UC.

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)· @TiansterZhang · X·2026-10-23 20:10· 2 天前评分70

正文 · 原文

#RandySweis showing data from EV-SG-zim in 1st line met #urothelialcancer — small sample size but high ORR 81% including 3 pts w CRs. Pushing depth of response for met UC.
@oncoalert #ESMO26 @myESMO

464 浏览 · 8 赞 · 8 转发 · 0 回复

会议摘要

1017P按 Developmental therapeutics 对上

Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors

https://esmocongress.esmo.org

NCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

https://esmocongress.esmo.org

来源：Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) · x.com